How your peers are using biomarker planning to optimize oncology trials.

In an era where unprecedented advances in our understanding of cancer biology have put personalized approaches to therapy in the spotlight, biomarkers are taking center stage in modern oncology drug development. Today, the process of developing oncology drugs is moving from a linear, phasic approach to a more flexible, iterative process that can be leveraged to accelerate proof of concept.

As biomarkers are increasingly used to define the most rational use for a drug, sponsors are facing critical operational considerations in the context of clinical trials. In addition, new technologies will need to be deployed to ingest and analyze the complex biological data generated by biomarker-driven trials to support and gain regulatory approval. In this white paper, we explore the growing importance of biomarkers in oncology development and discuss key considerations for optimizing the use of biomarkers in clinical trials.

Please fill the below form to download

Download